Phase I
Aptevo is a clinical-stage biotech company developing novel therapeutics built on its proprietary platform ADAPTIR™technology which is modular and includes bispecific molecules that recognize and bind to two unique target antigens simultaneously.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 3, 2020.
Regeneron announced on Friday that it is pausing dosing of garetosmab (REGN2477), an investigational therapy, in the Phase I LUMINA-1 trial.
Newly announced results of a Phase I dose-escalation study show CureVac’s COVID-19 vaccine candidate, CVnCoV, generates noticeable immune responses in healthy volunteers.
It was a particularly busy week for announcements about clinical trials, both related to COVID-19 and everything else. Here’s a look.
Q32 Bio rakes in $60 million Series B as they dose their first patient in IL-7R antibody trial.
On October 14th, Amolyt Pharma announced the first dosing in its Phase I trial of AZP-3601 in healthy subjects, a momentous occasion capping off years of hard work in pre-clinical development. The drug aims to walk the biological tightrope in the management of hypoparathyroidism, a rare disease causing muscular pain and cognitive challenges.
Recent Greenphire data shows new participant enrollment up 85% since slump in April.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 27, 2020.
It was another busy week for clinical trial updates and news. Here’s a look.
PRESS RELEASES